Business● Low5d ago · Oct 30, 2026, 6:00 AM
A pharma giant is moving past one patent cliff — but another is already looming
GlobeAlert Desk · curated from CNBC · global
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business30m agoAgilon raises 2026 outlook to $5.88B revenue and $150M adjusted EBITDA while expecting 40%-50% ACO membership growth in 2027Seeking Alpha TechBusiness30m agoTimken expects mid-single-digit 2027 organic sales growth as it raises 2026 adjusted EPS outlook to $6.35-$6.50Seeking Alpha TechBusiness40m agoSolstice outlines $4.195B-$4.22B 2026 sales outlook and plans to finish remaining $400M buyback by Q1 2027Seeking Alpha TechBusiness40m agoTraeger narrows FY 2026 outlook to $440M-$460M revenue as it expects Q4 return to YoY growth, supported by Lowe’s load-inSeeking Alpha Tech